There are no potential conflicts of interest to declare.
Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: Resolved and unresolved issues
Version of Record online: 19 DEC 2013
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd
Journal of Gastroenterology and Hepatology
Volume 29, Issue 1, pages 26–30, January 2014
How to Cite
Liu, C.-J. (2014), Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: Resolved and unresolved issues. Journal of Gastroenterology and Hepatology, 29: 26–30. doi: 10.1111/jgh.12421
- Issue online: 19 DEC 2013
- Version of Record online: 19 DEC 2013
- Accepted manuscript online: 7 NOV 2013 07:10AM EST
- Manuscript Accepted: 18 OCT 2013
- National Taiwan University Hospital
- Department of Health, Executive Yuan, Taiwan
- Taiwan Liver Disease Consortium (TLC), National Research Program for Biopharmaceuticals (NRPB), Taiwan. Grant Number: NSC100-2325-B-002-052
- 8An open label, comparative, multicenter study of peginterferon alfa-2a plus ribavirin in the treatment of patients with chronic hepatitis C/hepatitis B co-infection versus those with chronic hepatitis C monoinfection. Gastroenterology 2009; 136: 496–504., , et al.
- 18Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus. Korean J. Hepatol. 2011; 17: 199–205., , et al.
- 23European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J. Hepatol. 2011; 55: 245–264.
- 25European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57: 167–185.